Imatinib‐induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature

Tullio, Francesca Di; Mandel, Victor Desmond; Scotti, Rosa; Padalino, Claudia; Pellacani, Giovanni

doi:10.1111/ijd.13931

Cited by 30 publications

(9 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. 16 4 years 300 13 F Gingivae, teeth CML Alexandrescu et al 17 2 years (discontinued permanently) 600 50 M Skin GIST Lewis 18 3 years 800 70 M Oral Mucosa, Palate CML Mcpherson et al 19 6 years Unknown 59 F Oral Mucosa, fingernails CML Wong et al 20 3 months Unknown 43 F Palate CML Mattsson et al 21 5 22 9 years 400 48 M Oral mucosa CML Resende et al 23 5 years 600 38 M Palate, nose, earlobes Post-hematopoietic stem cell transplant Khoo et al 24 5 years 400 58 F Oral mucosa CML Roeker and Wolanskyj 25 6 years 400 65 F Palate CML Song and Kang 26 4 weeks 400 58 M Palate, nose CML Lyne et al 27 13 years 400-600 58 F Palate CML Romeo et al 28 11 years 400 72 F Palate CML Balasubramanian et al 29 6 months 400 60 F Face, extremities, chest CML Agrawal et al 30 6 months 400 32 F Teeth CML Bombeccari et al 31 9 years 400 63 M Palate CML Di Tullio et al 32 14 years 400-800 47 M Palate, extremities, nails CML…”

Section: Declaration Of Conflicting Interestsmentioning

confidence: 99%

Hyperpigmentation due to imatinib: A rare case of cutaneous involvement

Rehman

Hakim

Sugarman

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

Case report Imatinib mesylate is a well-known tyrosine kinase inhibitor used to treat chronic myeloid leukemia, gastrointestinal stromal tumor, as well as a variety of other malignancies. Management and outcome: As use of this medication continues to grow, providers must be aware of potential side effects and management thereof. The toxicity profile of imatinib has been well characterized with most patients experiencing a grade 1 or 2 adverse event. These side effects are usually mild, and most patients can continue treatment without interruption. Around 30% of patients on imatinib experience skin toxicity, with 5% being high grade. This rash is typically hypopigmented, which is explained by imatinib’s effect on melanocytes. Discussion Although there have been several case reports describing hyperpigmentation of the oral mucosa or nails, very few have described skin hyperpigmentation. We previously reported the first two cases of imatinib-related squamous cell carcinoma in patients undergoing treatment for gastrointestinal stromal tumors. In this paper, we present a case of a patient on imatinib for management of gastrointestinal stromal tumor who experienced extensive skin hyperpigmentation and review the literature.

show abstract

Section: Declaration Of Conflicting Interestsmentioning

confidence: 99%

Hyperpigmentation due to imatinib: A rare case of cutaneous involvement

Rehman

Hakim

Sugarman

et al. 2020

J Oncol Pharm Pract

View full text Add to dashboard Cite

show abstract

“…5 So far, thirty cases of hyperpigmentation of the oral mucosa, skin and nails have occurred secondary to imatinib. 6 A careful examination of the oral cavity may reveal the first manifestation of underlying systemic diseases. When the diagnosis cannot be reached clinically with enough certainty, a biopsy for histological examination is required, especially if malignancies such as melanoma are in the differential.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous Post Inflammatory Hyperpigmentation from Morsicatio Buccarum

Carrington¹

2021

DCIJ

View full text Add to dashboard Cite

Post Inflammatory hyperpigmentation (PIH) is a pigmentary phenomenon which commonly follows disease or injury. Examples include thermal or caustic burns, infections, or inflammatory disorders affecting the skin such as acne, atopic dermatitis, or rash. PIH can occur in anyone but is more common in Fitzpatrick types III-VI individuals, where the color tends to be more intense and persist for a longer period than in Fitzpatrick types I and II individuals. We present a unique case of PIH on the skin as a result of frequent biting of the inner buccal mucosa.

show abstract

“…However, even if a rare reaction, hyperpigmentation due to Imatinib can occur and the reason behind that needs to be elucidated. [19,20].…”

Section: Discussionmentioning

confidence: 99%

The L-PRF Membrane (Fibrin Rich in Platelets and Leukocytes) And Its Derivatives Useful as A Source of Stem Cells in Wound Surgery

2019

jscr

View full text Add to dashboard Cite

Introduction: Prostaglandin analogues (F2α) are often prescribed as first-line medical treatment for ocular hypertension or glaucoma. In this group of pharmacological agents, Latanoprost (0,005%) is the most commonly used and the first being indicated for paediatric patients. The main side effects are iris and periocular skin hyperpigmentation. Case presentation:We report the third case described in the literature of periocular skin hypopigmentation, in a patient treated with topical 0.005% Latanoprost. A female child developed periocular skin hypopigmentation in the right eye after two months of Latanoprost 0.005% use. In our patient, Latanoprost was preservative free while the other 2 cases described in literature contained Latanoprost with preservatives. Three months after Latanoprost discontinuation, peri-ocular hypopigmentation showed partial reversal, and stayed stable to the most recent follow-up in December 2018 (two years post discontinuation). Conclusion:Although periocular skin hyperpigmentation is a well-known side effect of Latanoprost, a paradoxical effect can occur with any drug and may be considered in patient's approach and treatment.

show abstract

Imatinib‐induced diffuse hyperpigmentation of the oral mucosa, the skin, and the nails in a patient affected by chronic myeloid leukemia: report of a case and review of the literature

Cited by 30 publications

References 18 publications

Hyperpigmentation due to imatinib: A rare case of cutaneous involvement

Hyperpigmentation due to imatinib: A rare case of cutaneous involvement

Cutaneous Post Inflammatory Hyperpigmentation from Morsicatio Buccarum

The L-PRF Membrane (Fibrin Rich in Platelets and Leukocytes) And Its Derivatives Useful as A Source of Stem Cells in Wound Surgery

Contact Info

Product

Resources

About